

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.co.jp/>

Restructuring of Group Companies

Tokyo, November 30, 2006—DAIICHI SANKYO COMPANY, LIMITED (hereafter: DAIICHI SANKYO) has decided to restructure its group companies as follows as a result of its acquisition of Sankyo Company Limited (hereafter; Sankyo) and Daiichi Pharmaceutical Co., Ltd. (hereafter; Daiichi Pharmaceutical).

1. Integration of healthcare businesses

Outline of new company (scheduled for April 1, 2007)

Company name	DAIICHI SANKYO HEALTHCARE CO., LTD.	
Business	Manufacture and trading of pharmaceutical products, quasi drugs, medical equipment, cosmetics, food products, beverages, etc.	
Main place of business	Head office (Tokyo); Research Center (Tokyo); Branches (7 locations)	
Location of head office	Chuo-ku, Tokyo	
Representatives	Chairman	Hidetoshi Imaizumi
	President	Moriya Ideguchi
	Executive Vice-President	Masaji Oe
Capital	¥100 million	
FY-end	March 31	

Outline of restructuring:

DAIICHI SANKYO HEALTHCARE will acquire Zepharm.

Outline of companies involved in restructuring (as of Sept. 30, 2006)

Company names	DAIICHI SANKYO HEALTHCARE CO., LTD.	Zepharm Inc.
Business	Manufacturing & marketing of pharmaceuticals, quasi-drugs, medical equipment, cosmetics, food products, beverages	Development and sale of pharmaceuticals, quasi-drugs, cosmetics, food products
Location of head office	Chuo-ku, Tokyo	Chuo-ku, Tokyo
Representatives	Moriya Ideguchi, President	Masaji Oe, President
Capital	¥100 million	¥300 million
Major shareholders & holding ratio	Sankyo: 67% Daiichi Pharmaceutical: 33%	DAIICHI SANKYO CO., LTD: 100%

2. Restructuring of subsidiaries

(1) Production subsidiary

Outline of new company (scheduled for April 1, 2007)

Company name	DAIICHI SANKYO PROPHARMA CO., LTD.	
Business	Manufacture, commissioned manufacture trading, import & export of pharmaceutical products	
Main place of business	Head office (Tokyo); factories (7 locations)	
Location of head office	Chuo-ku, Tokyo	
Representatives	President	Masahiro Okabe
	Executive Vice-President	Tatsuro Miyagawa
Capital	¥100 million	
FY-end	March 31	

Outline of restructuring:

DAIICHI SANKYO PROPHARMA CO., LTD., established in October 2006, will acquire Daiichi Pharmatech Co., Ltd., a subsidiary of Daiichi Pharmaceutical, and will acquire and divide the production division of Sankyo.

(2) R&D support subsidiaries

Outline of new company (April 1, 2007)

Company name	DAIICHI SANKYO RD ASSOCIE CO., LTD.
Business	Commissioned manufacture of test-use specimens and intermediates for use in R&D; consignment of screening tests; commissioned pharmacology tests; commissioned clinical test-related operations
Main place of business	Head office (Tokyo)
Location of head office	Shinagawa-ku, Tokyo
Representatives	President Tomio Kimura Executive Vice-President Toshiro Minotani
Capital	¥50 million
FY-end	March 31

Outline of restructuring

DAIICHI SANKYO RD ASSOCIE CO., LTD., established in October 2006, will acquire the Institute of Science and Technology, Inc. and Chemtec Labo., Inc. of the Sankyo Group and Kanto Daiichi Service Co., Ltd. of the Daiichi Pharmaceutical Group. Furthermore, a number of the R&D operations of the DAIICHI SANKYO Group will be transferred to Daiichi Sankyo RD Associe Co., Ltd.

(3) Management-support subsidiaries

Outline of the new company (Scheduled for April 1, 2007)

Company name	DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD.
Business	Consignment of personnel and accounting operations; leasing, management, buying & selling of real estate and real estate agency services; insurance agency services
Main place of business	Head office (Tokyo)

Representative	President Yoichi Hara Executive Vice-President Osamu Imada
Capital	¥50 million
FY-end	March 31

Outline of the restructuring

DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD., established in October 2006, will acquire Sankyo Insurance Agency Co., Ltd. and Godo Real Estate Co., Ltd. of the Sankyo Group and Daiichi Estate Co. Ltd. of the Daiichi Pharmaceutical Group. Furthermore, domestic personnel and accounting operations of the DAIICHI SANKYO Group will be transferred in part to DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD.

Other changes

(1) Logistics subsidiary

On April 1, 2007, we will change the name of Daiichi Butsuryu Co., Ltd. to DAIICHI SANKYO LOGISTICS CO., LTD. and will consolidate our domestic pharmaceutical distribution operations to this company.

(2) Special subsidiary

We will establish DAIICHI SANKYO HAPPINESS CO., LTD. in March 2, 2007, which will begin operations as a special subsidiary pursuant to the Law for Employment of Disabled Persons on April 2.

(3) Name of Daiichi Asubio Pharma Co., Ltd to change

As of April 1, 2007, the name of Daichi Asubio Pharma Co., Ltd. will change to ASUBIO PHARMA CO, LTD., while the name of its U.S. subsidiary Daiichi Asubio Pharmaceuticals, Inc. will change to ASUBIO PHARMACEUTICALS, INC.